Eisai Co., Ltd.
4-6-10, Koishikawa
Bunkyo-ku
Tokyo, 112-8088
Japan
Phone: 81 3 3817 3700
Website:
http://www.eisai.co.jp
Eisai Co., Ltd. manufactures and sells pharmaceutical products worldwide. The company offers oncology-related products, such as Halaven, an anticancer agent; Aloxi, an antiemetic agent; and Fragmin, an injectable anticlotting agent, as well as Symbenda/Treakisym, a treatment for low-grade non-Hodgkin's lymphoma and other types of lymphatic cancer. It also provides Aricept, an anti-Alzheimer's agent; Pariet/AcipHex, a proton-pump inhibitor; and Humira, a human anti-TNF-a monoclonal antibody. In addition, the company offers epilepsy products comprising Zonegran, Zebinix, and Fycompa, which are antiepileptic agents; and Inovelon/BANZEL for the treatment of Lennox-Gastaut syndrome, as well as consumer healthcare (over-the-counter) products, which include vitamin B2 preparation Chocola BB Plus. Further, it provides Methycobal, a peripheral neuropathy treatment; Warfarin, an oral anticoagulant; Actonel, an osteoporosis treatment; Selbex for the treatment of gastritis/gastric ulcer; BELVIQ, an antiobesity agent; Stronger Neo-Minophagen C/Glycyron tablets for liver disease/allergic disease treatment; Lyrica, a treatment for postherpetic neuralgia; and Lunesta, a treatment for insomnia. Additionally, the company is involved in the research and development of various products under the areas of oncology, vascular and immunological reaction, gastrointestinal and hepatic disorders, and neurology. It has strategic partnerships with Quintiles Inc.; SFJ Pharma Ltd.; Biogen Idec, Inc.; BioArctic Neuroscience AB; FORMA Therapeutics, Inc.; Epizyme, Inc.; PRISM BioLab Co., Ltd.; and Verastem, Inc. for the discovery and development of various products. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was founded in 1941 and is headquartered in Tokyo, Japan.